BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS).

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the “Board”), effective June 23, 2022.

Enzyvant announced it is among the National Organization for Rare Disorders 2022 Industry Innovation Awards recipients for the development and U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for pediatric congenital athymia.

Maravai LifeSciences, Inc. announced that Peter Leddy, Ph.D. has joined the Company as Executive Vice President and Chief Administrative Officer.

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder.

SELLAS Life Sciences Group, Inc. today provided a clinical update on the ongoing Phase 1 dose-escalating clinical trial of GFH009, its novel and highly selective CDK9 inhibitor, in advanced relapsed and refractory lymphoma and acute myeloid leukemia (AML).

MAPS Public Benefit Corporation (MAPS PBC) announced today that it has selected MMS Holdings (MMS), an award-winning data-focused contract research organization (CRO) as its contract research organization for the development of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD).

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to announce the successful completion of its pre-clinical pharmacokinetic study - IM032 - in male beagle dogs comparing intramuscular (“IM”) and subcutaneous (“SC”) dosing of Soluvec™ 1% with oral administration of commercially available branded ivermectin.

Kuria is granted exclusive worldwide rights to develop, manufacture, and commercialize asset for ocular and dermatologic diseases with localized therapeutic application; SCOHIA PHARMA to receive upfront payment plus up to 67 million USD in potential regulatory, development, and commercial milestones.